Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

The outbreak of Hantavirus on a cruise ship has led to biotech and pharmaceutical stocks surging on reports of firms ...

This genetic disorder treatment developer's stock hit a buy point after the biotech's first-quarter earnings report last week ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

This biotech firm develops therapies for rare pulmonary diseases, leveraging proprietary drug delivery technology in the U.S.

Intel, Qualcomm, and Micron fall as investors opt to lock in profits following a breakneck rally in chip stocks. Trump’s China summit threatens the AI boom, Ford gets into the energy storage business, ...

Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, ...

CBSET plans to build a 110K SF life sciences facility in Waltham, the Boston Business Journal first reported. The new ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the ...

Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%.

If any proof was needed that big money is still available for AI drug development, look no further than the ten-figure series B hauled in by Isomorphic Labs. The London-based AI drug discovery firm ...